Journal September 27, 2026 7 min read

Which peptides are studied in relation to oxidative stress?

A research-supply overview of peptides and related compounds investigated in oxidative-stress models, including mitochondrial-derived peptides, glutathione-pathway agents, and adjunctive antioxidants. All content is for

peptides-pro Editorial

Peptides studied in relation to oxidative stress are a heterogeneous set of short-chain amino-acid polymers and peptide-adjacent small molecules that appear in preclinical and clinical research on redox balance, mitochondrial function, and antioxidant defence. The most directly named peptide in the supplied evidence is the mitochondrial-derived peptide SHLP2 (small humanin-like peptide 2), which has been examined in alveolar epithelial injury models [10]. Other compounds in this space are not peptides in the strict sense but are studied alongside them because they intersect the same redox pathways: N-acetylcysteine (NAC), a cysteine prodrug and glutathione precursor [4]; nicotinamide riboside (NR), a nicotinamide adenine dinucleotide (NAD+) precursor [3]; melatonin [6]; vitamin E [1]; zinc [2]; vitamin D [8]; and the diet-derived compound ergothioneine [12].

Where the evidence provides identifiers, they are limited. The supplied records do not give sequence, molecular formula, or molecular weight for SHLP2 or for the other compounds listed. The work centres on the glutathione and thioredoxin antioxidant systems, mitochondrial redox regulation, and the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway, with GPX4 (glutathione peroxidase 4) named as a specific enzyme marker in surgical healing research [5].

Research Studies

SHLP2 and Poly(I:C)-induced alveolar epithelial injury

In a preclinical study, the mitochondrial peptide SHLP2 was investigated in type II alveolar epithelial (ATII) cells exposed to polyinosinic:polycytidylic acid [Poly(I:C)], a synthetic analogue of viral double-stranded RNA. Poly(I:C) induced a viral-like epithelial injury phenotype characterised by oxidative stress and mitochondrial disruption. The work reported that SHLP2 limited this injury by modulating redox, apoptotic, inflammatory, and inflammasome responses [10]. This is an in vitro or preclinical finding; no human dosing or outcome data are provided in the evidence.

N-acetylcysteine and repetitive behaviours in Cornelia de Lange syndrome

A randomised cross-over pilot trial tested N-acetylcysteine (NAC) for repetitive behaviours (RB) and self-injurious behaviour (SIB) in patients with Cornelia de Lange syndrome (CdLS), a genetic disorder with autistic features. NAC is described in the record as a known anti-oxidative stress and neuroprotective agent that has been shown to decrease the occurrence of SIB such as skin picking, and it has shown partial response in trials for compulsive behaviours in obsessive-compulsive disorder and related disorders in autism [4]. The population is patients with CdLS; the trial is a pilot, and the evidence does not report efficacy results.

Nicotinamide riboside and walking distance in peripheral artery disease

The NICE-PAD II trial is randomising 250 participants with peripheral artery disease (PAD) age 50 and older to nicotinamide riboside (NR) or placebo for six months. The primary outcome is change in six-minute walk distance at six-month follow-up. Secondary outcomes include Walking Impairment Questionnaire (WIQ) distance score, PROMIS Mobility score, and calf muscle perfusion measured by magnetic resonance arterial spin labelling [3]. The hypothesis is that NR will produce greater improvement or less decline in six-minute walk distance than placebo. The population is adults with PAD; results are not yet reported in the evidence.

Melatonin and atopic dermatitis severity

A randomised controlled trial is evaluating oral melatonin as an adjunct to standard treatment in adults with atopic dermatitis. A total of 130 participants will be assigned 1:1 to standard treatment according to the Vietnamese Ministry of Health 2023 guideline or standard treatment plus oral melatonin 6 mg once daily for 4 weeks. Atopic dermatitis severity will be assessed using the SCORing Atopic Dermatitis index. The record notes that melatonin may have beneficial effects on sleep, inflammation, and oxidative stress [6]. The population is adults with atopic dermatitis; the evidence does not report outcomes.

Vitamin E and oxidative stress in levothyroxine-treated hypothyroidism

A clinical trial is investigating whether vitamin E supplementation as an adjunct to levothyroxine therapy reduces oxidative stress, improves antioxidant defence mechanisms, and favourably influences thyroid hormone status in patients with hypothyroidism. The stated aim is to establish an evidence-based framework for integrating targeted antioxidant therapies into standard hypothyroid management [1]. The population is levothyroxine-treated hypothyroid patients; the evidence does not report results.

Zinc and insulin resistance in polyendocrine metabolic ovarian syndrome

A trial is examining zinc supplementation in women with polyendocrine metabolic ovarian syndrome (PMOS), an endocrinopathy mechanistically anchored in insulin resistance. The record states that South Asian women, including Bangladeshi women, develop insulin resistance at lower BMI thresholds than other populations and simultaneously carry a high burden of zinc deficiency, reported as 57% of non-pregnant non-lactating women. Zinc is described as structurally required for pancreatic β-cell insulin synthesis, as modulating insulin-receptor signalling and PI3K/Akt-mediated glucose uptake, and as a cofactor for Cu/Zn-superoxide dismutase [2]. The population is women with PMOS; the evidence does not report outcomes.

Vitamin D and diabetic peripheral neuropathy

A clinical trial is studying vitamin D in diabetic peripheral neuropathy (DPN). The record describes DPN pathogenesis as multifactorial, involving oxidative stress, chronic inflammation, endothelial dysfunction, mitochondrial injury, and microvascular ischaemia, leading to progressive nerve damage. Existing symptomatic therapies include gabapentin, pregabalin, and duloxetine, and many patients continue to experience persistent neuropathic symptoms, poor sleep quality, and impaired daily function [8]. The population is patients with DPN; the evidence does not report results.

GPX4 expression after Kono-S versus conventional anastomosis in Crohn's disease

A study is exploring how the bowel heals after surgery in Crohn's disease by examining oxidative stress and GPX4 expression after Kono-S anastomosis compared with conventional anastomosis. The Kono-S approach is designed to reduce the risk of Crohn's disease recurrence near the join where the bowel has been reconnected; early results are described as promising, but the mechanism is not fully understood [5]. The population is patients with Crohn's disease undergoing bowel surgery; the evidence does not report results.

Light therapy and oxidative stress markers in healthy adults and type 1 diabetes

A clinical trial is evaluating low-level light therapy on cellular energy and oxidative stress in healthy adults and patients with type 1 diabetes. The main questions are whether light therapy changes adenosine triphosphate (ATP) levels and cytochrome c oxidase activity in blood cells, and how the intervention affects oxidative stress markers, specifically glutathione and malondialdehyde concentrations. Blood samples collected before and after light therapy are compared to assess mitochondrial function, and responses of healthy volunteers are compared with those of diabetic patients [7]. The populations are healthy adults and patients with type 1 diabetes; the evidence does not report results.

Ergothioneine and mitochondrial redox regulation

A review describes ergothioneine as a diet-derived xenobiotic with OCTN1-mediated disposition and mitochondrial redox regulation, with emerging implications for cardiovascular disease. The record notes that mitochondrial dysfunction is a convergent upstream driver of cardiovascular disease, linking energetic failure, oxidative stress, inflammation, and maladaptive remodelling, and that inconsistent results of conventional antioxidant trials are likely due to multiple factors including compound selection and dose [12]. This is a review; it does not report new primary data.

Comparison of compounds and evidence stage

Compound	Class	Population or model	Evidence stage in supplied record
SHLP2	Mitochondrial-derived peptide	ATII cells, Poly(I:C) injury	Preclinical / in vitro [10]
N-acetylcysteine	Cysteine prodrug, glutathione precursor	Patients with Cornelia de Lange syndrome	Randomised cross-over pilot trial [4]
Nicotinamide riboside	NAD+ precursor	Adults with peripheral artery disease	Randomised trial, 250 participants [3]
Melatonin	Indoleamine hormone	Adults with atopic dermatitis	Randomised controlled trial, 130 participants [6]
Vitamin E	Lipid-soluble antioxidant	Levothyroxine-treated hypothyroid patients	Clinical trial [1]
Zinc	Trace element, enzyme cofactor	Women with PMOS	Clinical trial [2]
Vitamin D	Secosteroid hormone	Patients with diabetic peripheral neuropathy	Clinical trial [8]
Ergothioneine	Diet-derived xenobiotic	Cardiovascular disease context	Review [12]

Related reference-only findings

Two reference-only papers support the broader redox context. One reports that ALKBH5-dependent m6A demethylation promotes cardiac aging through SLC38A3 reduction and glutamine metabolic alteration [9]. Another is a scoping review of coffee and coffee-derived bioactive compounds in skeletal muscle health, covering mechanistic pathways, preclinical evidence, and human outcomes [11]. These are cited as background and are not the subject of the sections above.

If you are reading this for personal health reasons

The compounds described here are sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is a recommendation for human use.